Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.

Sergio Bracarda,Aristotelis Bamias,Jochen Casper,Sylvie Negrier,Avishay Sella,Michael Staehler,Jamal Tarazi,Alessandra Felici,Brad Rosbrook, Monica Jardinaud-Lopez,Bernard Escudier

Clinical Genitourinary Cancer（2019）

引用 13|浏览62

暂无评分

摘要

In patients with mRCC, axitinib remains a suitable second-line treatment option across multiple subgroups. A relevant reduction in the risk of a PFS event was observed for axitinib compared to sorafenib in selected subgroups of patients.

查看译文

关键词

Favorable/intermediate risk,Metastatic renal-cell carcinoma,Prognostic factors,Progression-free survival,Sorafenib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要